TP53 and prostate carcinoma: While there is currently no direct evidence linking the patient’s prior treatment for hepatocellular carcinoma, which included interventional embolization and radiofrequency ablation, to the subsequent development of prostate cancer and chronic lymphocytic leukemia (CLL), it is conceivable that these therapeutic interventions may have altered the internal microenvironment or exerted selection pressures that facilitated the expansion of TP53-mutant clones.